- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT06867302
Dexmedetomidina y agitación después de la cirugía nasal
Efectividad del bolo único versus la infusión continua de dexmedetomidina en la agitación mitigante en adultos sometidos a cirugía nasal: un ensayo prospectivo aleatorizado
The main objective of study is to compare dexmedetomidine single bolus dose before extubation with continuous infusion as regards their efficacy in mitigating the incidence of emergence agitation in obese adults undergoing nasal surgery.
Descripción general del estudio
Estado
Condiciones
Descripción detallada
Agitation during emergence from general anesthesia is a potentially serious phenomenon that has not been studied in adults as often as in pediatric population. When agitation, serious self-injury, or violence towards the medical team occur, with the risk of aspiration, bleeding, hypoxia, arrhythmias, or simply pulling the endotracheal tubes, removal of drains or catheters. Moreover, agitated patients are not only at risk of developing complications but also, they are labor intensive as they require more medical attention, rescue drugs, and more attending staff till agitation attack safely subside. Recognized risk factors to develop emergence agitation (EA) in adults include ear, nose, and throat surgery, obesity, sevoflurane anesthesia, endotracheal tube, and history of psychological illness. In adults, adjuvants have been co-administered with general anesthesia in order to negate or reduce the incidence of EA especially in patients with identified risk factors.
dexmedetomidine is a highly selective α2 sympatholytic, has been proposed as an attractive candidate for the prophylaxis of EA. By interacting with α2 receptors in locus coeruleus of the pons, Dex exerts its unique anxiolytic, sedative and sympathetic antagonistic action with no respiratory depression. Moreover, it has pain-modulating effect due to interaction with α2 receptor sites in the dorsal horn and supra-spinal regions.
Nevertheless, there have been conflicting data about Dex optimal dose and time of administration when used as prophylaxis against EA. Indeed, different dosing protocols are associated with over sedation, prolonged extubation time, and delayed post-anaesthesia care unit time.
No premedication. Basic general anesthesia monitoring included electrocardiogram, pulse oximetry, non-invasive arterial pressure, and capnography, were recorded every 5 min. Preoxygenation with 100% oxygen for 5 min was performed before fentanyl 1 μg/kg and propofol 1.5-2 mg/ kg, were administered as induction agents. Intubation with facilitated with atracurium besylate 0.5 mg/ kg. The size of endotracheal tubes was 6.5-7.5 mm, for females and males, respectively. Mechanical ventilation was set on 6 ml/kg tidal volume, and respiratory rate was adjusted to keep end-tidal CO2 between 35 and 40 mmHg, in 50% O2/air. All patients at induction were given dexamethasone 4 mg i.v., ondansetron, 4 mg i.v to prevent post-operative nausea and vomiting, plus Ringers lactate solution 6 mg/ kg drip for basic volume maintenance. Blood loss was compensated for with Ringers lactate, intraoperatively. Maintenance of anesthesia was carried out with Isoflurane, regulated at 2-3%, Titrated incremental doses of atropine 0.5 mg, esmolol 10 mg, and ephedrine 6 mg were given i.v., when HR ≤ 45, HR ≥ 120 and MAP ≤ 60, in the mentioned order. ketorolac 30 mg was given I.M., at the time of nasal packing.
When surgery was finished, gentle suction was attempted, non-depolarizing muscle relaxant reverse with atropine, 0.5 mg and neostigmine 0.02 mg/kg was given. Next, isoflurane was turned off and respiration was then converted back to manual ventilation with 100% oxygen at 7 L/min. The patients were not disturbed, except by continual verbal requests to open their eyes. All other stimuli were prevented. Extubation was done when patients were able to breathe spontaneously and interact with verbal demands. When patients were awake, calm, and sedated, they were transferred to the PACU. Patients were discharged from the PACU when their Aldrete score was ≥ 9.
Statistical analysis:
Statistical analysis will be conducted using IBM SPSS Statistics 22 (IBM Corporation, USA). The normal distribution of data will be assessed by the Kolmogorov-Smirnov and Shapiro-Wilk tests. Mean and standard deviation will be used as descriptive statistics for normally distributed numerical variables, while median and interquartile range (25th to 75th percentiles) will be used as descriptive statistics for non-normally distributed numerical variables. In addition, Chi-square test or fisher exact test will be employed to test the significance between categorical variables as appropriate. Independent t test will be employed for numerical data that exhibited normal distribution, whereas the Mann-Whitney test will be used for numerical data that did not adhere to normal distribution. A significance level of p < 0.05 will be deemed to be statistically significant.
Tipo de estudio
Inscripción (Estimado)
Fase
- No aplica
Contactos y Ubicaciones
Estudio Contacto
- Nombre: Yasser S Mostafa, MD
- Número de teléfono: +2 01010509735
- Correo electrónico: ysm03@fayoum.edu.eg
Copia de seguridad de contactos de estudio
- Nombre: Mohamed A Shawky, MD
- Número de teléfono: +2 0 109 525 4547
- Correo electrónico: mas14@fayoum.edu.eg
Ubicaciones de estudio
-
-
Faiyum Governorate
-
Al Fayyum, Faiyum Governorate, Egipto, 63514
- Reclutamiento
- Fayoum University Hospital
-
Contacto:
- Yasser S Mostafa, MD.
- Número de teléfono: +2 01010509735
- Correo electrónico: ysm03@fayoum.edu.eg
-
Contacto:
- Mohamed A Shawky, MD
- Número de teléfono: +2 01095254547
- Correo electrónico: mas14@fayoum.edu.eg
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
- American Society of Anesthesiologist (ASA) Ⅰ or II
- Adults with body mass index (BMI) < 30 Kg/m
- Underwent elective nasal surgery.
Exclusion Criteria:
- Significant comorbidity like hepatic, renal, or cardiac disease
- Auditory impairment
- Cognitive dysfunction
- Substance abuse
- Allergy to the studied medicines
- Planned intensive care admission after the surgery.
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Prevención
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación paralela
- Enmascaramiento: Triple
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
|---|---|
|
Experimental: Bolus group
single dose 0.5 µg/kg in 15 ml saline over 10 min , started 15 minutes before end of surgery |
An infusion given all through intraoperative time
Otros nombres:
|
|
Experimental: Infusion group
Infusion of dexmedetomidine at a dose of 0.5 µg/kg/h without loading dose all through intraoperative time |
Single dose given 15 minutes before end of surgery
Otros nombres:
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Degree of emergence agitation by Richmond Agitation Sedation Scale (RASS)
Periodo de tiempo: 5 minutes after operation
|
RASS is a 10-point scoring system used to assess patient's level of agitation and sedation: 4 levels for agitation, 1 level for normal (alert and calm), and 5 levels of sedation |
5 minutes after operation
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Intraoperative heart rate
Periodo de tiempo: Every 15 minutes along operation
|
Beats / minute |
Every 15 minutes along operation
|
|
Intraoperative mean arterial blood pressure
Periodo de tiempo: Every 15 minutes along operation
|
mmHg |
Every 15 minutes along operation
|
|
Time of first rescue analgesic
Periodo de tiempo: 5 minutes before first analgesic request
|
in minutes in minutes |
5 minutes before first analgesic request
|
|
Extubation time
Periodo de tiempo: 3 minutes after removal of endotracheal tube
|
time interval between shutting off anesthetics to extubation (in minutes) |
3 minutes after removal of endotracheal tube
|
|
Postanesthesia care unit time
Periodo de tiempo: 5 minutes after discharge from recovery unit
|
time interval from admission to PACU till patient scored ≥ 9 on Aldrete scale (ready to discharge) |
5 minutes after discharge from recovery unit
|
|
Incidence of use of midazolam
Periodo de tiempo: 2 minutes after occurence of emergence agitation
|
Yes or no |
2 minutes after occurence of emergence agitation
|
|
Numerical rating score (NRS)
Periodo de tiempo: Every 10 min in postanesthesia care unit
|
10 point scale where zero meaning "no pain" and 10 meaning "the worst pain imaginable" |
Every 10 min in postanesthesia care unit
|
|
Total amount of rescue analgesic
Periodo de tiempo: 24 hours postoperative
|
in milligram |
24 hours postoperative
|
|
Boezaart Surgical Field Grading Scale
Periodo de tiempo: 2 hours intraoperatively
|
endoscopically using the six-point score (0-5 Scale) where 0 - No bleeding, 1 - Slight bleeding, no suctioning needed, 2 - Slight bleeding, occasional suctioning needed, 3 - Moderate bleeding, frequent suctioning needed, visibility maintained, 4 - Heavy bleeding, constant suctioning needed, visibility impaired, 5 - Severe bleeding, uncontrolled, surgery impossible |
2 hours intraoperatively
|
|
Incidence of bradycardia
Periodo de tiempo: 2 hours intraoperatively
|
Yes or no |
2 hours intraoperatively
|
|
Incidence of hypotension
Periodo de tiempo: 2 hours intraoperatively
|
Yes or no when mean arterial blood pressure below 60 mmHg |
2 hours intraoperatively
|
|
Incidence of nausea
Periodo de tiempo: 24 hours postoperative
|
Yes or no |
24 hours postoperative
|
|
Incidence of vomiting
Periodo de tiempo: 24 hours postoperative
|
Yes or no |
24 hours postoperative
|
Otras medidas de resultado
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Age
Periodo de tiempo: 5 minutes before entering operation department
|
in years |
5 minutes before entering operation department
|
|
Sex
Periodo de tiempo: 5 minutes before entering operation department
|
Male of female |
5 minutes before entering operation department
|
|
Weight
Periodo de tiempo: 5 minutes before entering operation department
|
In kilogram |
5 minutes before entering operation department
|
|
Height
Periodo de tiempo: 5 minutes before entering operation department
|
In centimeter |
5 minutes before entering operation department
|
|
Duration of surgery
Periodo de tiempo: 5 minutes after end of surgery
|
In minutes |
5 minutes after end of surgery
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Investigador principal: Yasser S Mostafa, MD, Fayoum University
- Silla de estudio: Mohamed A Shawky, MD, Fayoum University
Publicaciones y enlaces útiles
Publicaciones Generales
- Lepouse C, Lautner CA, Liu L, Gomis P, Leon A. Emergence delirium in adults in the post-anaesthesia care unit. Br J Anaesth. 2006 Jun;96(6):747-53. doi: 10.1093/bja/ael094. Epub 2006 May 2.
- Yu D, Chai W, Sun X, Yao L. Emergence agitation in adults: risk factors in 2,000 patients. Can J Anaesth. 2010 Sep;57(9):843-8. doi: 10.1007/s12630-010-9338-9. Epub 2010 Jun 5.
- Hudek K. Emergence delirium: a nursing perspective. AORN J. 2009 Mar;89(3):509-16; quiz 517-9. doi: 10.1016/j.aorn.2008.12.026.
- Kim HJ, Kim DK, Kim HY, Kim JK, Choi SW. Risk factors of emergence agitation in adults undergoing general anesthesia for nasal surgery. Clin Exp Otorhinolaryngol. 2015 Mar;8(1):46-51. doi: 10.3342/ceo.2015.8.1.46. Epub 2015 Feb 3.
- Zhu M, Wang H, Zhu A, Niu K, Wang G. Meta-analysis of dexmedetomidine on emergence agitation and recovery profiles in children after sevoflurane anesthesia: different administration and different dosage. PLoS One. 2015 Apr 13;10(4):e0123728. doi: 10.1371/journal.pone.0123728. eCollection 2015.
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Finalización primaria (Estimado)
Finalización del estudio (Estimado)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
- Manifestaciones neurológicas
- Enfermedades del Sistema Nervioso
- Desordenes mentales
- Complicaciones Postoperatorias
- Procesos Patológicos
- Enfermedades de las vías respiratorias
- Confusión
- Manifestaciones neuroconductuales
- Trastornos neurocognitivos
- Enfermedades Otorrinolaringológicas
- Delirio
- Condiciones Patológicas, Signos y Síntomas
- Signos y síntomas
- Delirio de emergencia
- Enfermedades de la nariz
- Compuestos heterocíclicos, 1 anillo
- Compuestos heterocíclicos
- Azoles
- Imidazoles
- Dexmedetomidina
Otros números de identificación del estudio
- R656
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .